Biomarker Development Program
Neurological Disorders
ResearchActive
Key Facts
About NeuroVision Imaging
NeuroVision Imaging is a private, venture-backed company addressing critical gaps in the neurology care pathway through a dual-platform strategy. Its core technology, the Afina Retinal Imaging platform, uses AI to detect amyloid signatures in the retina as a non-invasive biomarker for Alzheimer's and Cerebral Amyloid Angiopathy (CAA). Concurrently, the company's BrainHealth.net telehealth platform offers scalable diagnostic and managed services, including patient triage, preventative neurology coaching, genetic testing, and clinical trial matching, aiming to improve access and outcomes in cognitive healthcare.
View full company profileTherapeutic Areas
Other Neurological Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| GlyT2 Inhibitor Program | Micar Innovation | Discovery |
| Biomarker Discovery & Validation Services | NeuroDex | Service |
| Clinical Trial Biomarker Support | NeuroDex | Service |
| CNS-Targeting Capsids | rAAVen Therapeutics | Pre-clinical |
| IVL-002 | InVirtuoLabs | Discovery |
| IVL-003 | InVirtuoLabs | Discovery |
| Neurology Diagnostics Program | Aptus Biosciences | Discovery |
| GM1 Ganglioside-based Therapies | TRB Chemedica International | Commercial / Development |
| Undisclosed Neurology Programs | BridGene Biosciences | Discovery |
| iPSC Platform Programs | Evotec | Preclinical Research |
| ExacTcell Platform | Tevogen Bio | Discovery/Preclinical |